AHMED NADIM 4

What Happened
Ahmed Nadim, a director of Disc Medicine, was granted a derivative equity award (reported as an option) covering 5,176 shares on 2026-06-18. The Form 4 lists the acquisition price as $0.00 and a reported value of $0 — this is an issuance of compensation equity, not a market purchase or sale.

Key Details

• Transaction date: 2026-06-18
• Filing date: 2026-06-23 (appears to be filed one business day late; Form 4 generally must be filed within two business days of the transaction)
• Transaction type/code: Grant/award of a derivative security (A) — option award
• Shares/units granted: 5,176 underlying shares
• Price/value reported: $0.00 / $0 reported
• Vesting (footnote): Vests on the earlier of (i) the Company’s 2027 annual meeting or (ii) the one-year anniversary of the grant, subject to continued service (per footnote F1)
• Shares owned after transaction: Not disclosed in the provided filing

Context
This was an equity compensation grant to a director (not a purchase or sale). Such awards are common for directors and typically subject to service/vesting conditions, so they do not by themselves signal an immediate buying/selling intention. The late filing is administrative information investors may note but does not by itself explain the grant’s purpose.